Compare Lithium Americas Corp (LAC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs TransMedics Group Inc — how do they compare? Lithium Americas Corp trades at $3.27 (market cap $1.18B), while TransMedics Group Inc trades at $87.14 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 2.6× Lithium Americas Corp's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.
| LAC | TMDX | |
|---|---|---|
Market Cap | $1.18B | $3.10B |
Sector | Basic Materials | Technology |
52-Week High | $10.05 | $150.42 |
52-Week Low | $2.71 | $61.99 |
Enterprise Value | $1.29B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $3.25 with mixed technical signals showing a bullish overall trend but neutral oscillators. The company reported negative profitability metrics with ROE at -11.35% and net income of -$122.09M for 2025, though it secured $175M financing for Thacker Pass construction. Recent earnings show volatility with two beats and one miss in the last four quarters.
LAC faces significant execution risks with substantial capital expenditures needed, but analyst sentiment remains positive with 7 buy ratings and no sell recommendations. The stock's valuation at 0.88 P/B suggests potential upside if lithium demand recovers, though negative cash flow from operations and high investing outflows present near-term challenges.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
